165 related articles for article (PubMed ID: 16750360)
1. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.
Mahale S; Aubry C; James Wilson A; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Med Chem Lett; 2006 Aug; 16(16):4272-8. PubMed ID: 16750360
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.
Soni R; Muller L; Furet P; Schoepfer J; Stephan C; Zumstein-Mecker S; Fretz H; Chaudhuri B
Biochem Biophys Res Commun; 2000 Sep; 275(3):877-84. PubMed ID: 10973815
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
5. Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.
Mahale S; Bharate SB; Manda S; Joshi P; Bharate SS; Jenkins PR; Vishwakarma RA; Chaudhuri B
J Med Chem; 2014 Nov; 57(22):9658-72. PubMed ID: 25368960
[TBL] [Abstract][Full Text] [Related]
6. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
7. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
9. Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
Schmitz NM; Hirt A; Aebi M; Leibundgut K
Am J Pathol; 2006 Sep; 169(3):1074-9. PubMed ID: 16936279
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
11. Saucernetin-7 isolated from Saururus chinensis inhibits proliferation of human promyelocytic HL-60 leukemia cells via G0/G1 phase arrest and induction of differentiation.
Seo BR; Lee KW; Ha J; Park HJ; Choi JW; Lee KT
Carcinogenesis; 2004 Aug; 25(8):1387-94. PubMed ID: 15033903
[TBL] [Abstract][Full Text] [Related]
12. Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization.
Mahale S; Bharate SB; Manda S; Joshi P; Jenkins PR; Vishwakarma RA; Chaudhuri B
Cell Death Dis; 2015 May; 6(5):e1743. PubMed ID: 25950473
[TBL] [Abstract][Full Text] [Related]
13. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
Shafiq MI; Steinbrecher T; Schmid R
PLoS One; 2012; 7(8):e42612. PubMed ID: 22905154
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts.
Gaben AM; Saucier C; Bedin M; Barbu V; Mester J
Int J Cancer; 2004 Jan; 108(2):200-6. PubMed ID: 14639603
[TBL] [Abstract][Full Text] [Related]
15. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
17. Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells.
Lee SH; Park C; Jin CY; Kim GY; Moon SK; Hyun JW; Lee WH; Choi BT; Kwon TK; Yoo YH; Choi YH
Biomed Pharmacother; 2008 Dec; 62(10):723-9. PubMed ID: 18222060
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel inhibitors of cyclin-dependent kinases.
Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
[TBL] [Abstract][Full Text] [Related]
19. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
20. Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D3 display increased CDK2 and CDK6 activity and shortened G1 phase.
Wang QM; Luo X; Kheir A; Coffman FD; Studzinski GP
Oncogene; 1998 May; 16(21):2729-37. PubMed ID: 9652739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
